To test the efficacy and dosing of a biologic human growth factor concentrate (GFC-01) in promoting wound healing using a diabetic rat model

This research project evaluates the efficacy and dosing of a biologic human growth factor concentrate (GFC-01) for promoting wound healing in a diabetic rat model. Within COMP’s strong translational research mission and bench-to-bedside approach, the study is positioned to bridge basic science and clinical application by rigorously testing a candidate biologic therapy under controlled preclinical conditions. The core objectives are to determine whether GFC-01 accelerates or improves wound repair in diabetic physiology and to identify dosing parameters that maximize therapeutic benefit while informing future translational steps. Utilizing a diabetic rat model allows the research team to simulate impaired wound-healing environments commonly encountered in patients with diabetes, enabling assessment of treatment effects on relevant biological endpoints.

Primary experimental components include standardized creation of cutaneous wounds in diabetic rats, administration of GFC-01 at multiple dose levels, and systematic monitoring of wound closure rates, tissue regeneration markers, and any observable adverse effects. Quantitative measures of wound area reduction over time, histological evaluation of newly formed tissue, and assessment of cellular and molecular indicators of healing will be used to compare treated and control groups. By exploring dose–response relationships, the project aims to define a dosing regimen that yields robust therapeutic responses and to generate preclinical safety and efficacy data necessary for subsequent translational development. Conducted within COMP’s Department of Translational Research and informed by the college’s integrated systems-based curriculum and emphasis on translational and clinical research, this work embodies the institution’s commitment to producing clinically relevant scientific advances.

Outcomes from this research are expected to contribute to the evidence base regarding biologic growth factor concentrates as therapeutic agents in impaired wound healing, particularly in diabetic contexts where clinical need is substantial. Data on efficacy and optimized dosing will be critical for designing subsequent studies, including larger preclinical trials or early-phase clinical investigations, and will assist in delineating the translational pathway for GFC-01. Through careful experimental design, transparent reporting of methods and results, and adherence to translational research principles, this investigation seeks to generate reproducible, clinically meaningful findings that advance understanding of growth factor–based therapies for wound repair.